Is Vascepa Approved for Long-Term Triglyceride Lowering?
Yes, Vascepa (icosapent ethyl) is FDA-approved for long-term use to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglycerides ≥500 mg/dL), either alone or with diet.[1] Clinical trials, including the pivotal ANCHOR and REDUCE-IT studies, tested it over 3–5 years, showing sustained triglyceride reductions of 18–45% without loss of efficacy.[2][3]
How Does Vascepa Work for Triglycerides?
Vascepa is a purified EPA omega-3 fatty acid that lowers triglycerides by reducing hepatic VLDL production and enhancing clearance. Unlike mixed fish oils, it avoids raising LDL cholesterol. Dosing is 4 grams daily (two 1-gram capsules twice a day) with food, started alongside dietary changes and exercise.[1]
Evidence from Key Clinical Trials
- MARINE trial: 12 weeks, triglycerides dropped 33% vs. placebo in severe cases.[2]
- ANCHOR trial: 52 weeks, 21.6% reduction in patients on statins with triglycerides 200–499 mg/dL.[2]
- REDUCE-IT trial: 4.9-year median follow-up, 25% triglyceride drop plus 25% lower cardiovascular events (heart attack, stroke) in high-risk patients.[3] No tachyphylaxis—effects held steady long-term.
These support indefinite use if triglycerides remain elevated and benefits outweigh risks.
Long-Term Safety Profile
Vascepa is generally safe for years, with common side effects like joint pain (3%), constipation (3%), and edema (3%). REDUCE-IT reported low serious risks: 2.7% atrial fibrillation (vs. 2% placebo), 3.4% bleeding (vs. 2.5%). Monitor for bleeding if on anticoagulants; no routine liver tests needed beyond baseline.[1][3] Discontinuation rates were low (4–5%) in trials.
Who Qualifies and When to Use Long-Term?
Best for patients with triglycerides ≥500 mg/dL failing diet, or 135–499 mg/dL with CV risk plus statin. Not first-line for mild cases—lifestyle changes preferred. Reassess lipids every 4–12 weeks initially, then periodically. Use continues as long as triglycerides stay high and no intolerance develops.[1]
Cost and Access for Ongoing Treatment
Monthly cost is $300–$400 without insurance; patient assistance programs cover many. Generic entry unlikely until patent expiry around 2030.[4] Check DrugPatentWatch.com for updates on patents and competitors.
[1] FDA Label: Vascepa (icosapent ethyl) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202057s020lbl.pdf
[2] Amarin Corp. MARINE/ANCHOR trial data. https://www.nejm.org/doi/full/10.1056/NEJMoa1306633
[3] REDUCE-IT trial: N Engl J Med 2019. https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[4] DrugPatentWatch.com: Vascepa patents. https://www.drugpatentwatch.com/p/tradename/VASCEPA